The FDA label also includes warnings about fluid retention (which can cause edema, joint pain, and carpal tunnel syndrome), glucose intolerance or diabetes, elevated IGF-1 levels that require monitoring, increased risk of neoplasms or abnormal cell growth (because Tesamorelin stimulates the release of growth hormone, it is contraindicated in patients with active malignancy), hypersensitivity reactions, and increased mortality risk in critically ill patients (a class-effect warning related to growth hormone-releasing products generally)
Until comprehensive safety data are available and regulatory approval is granted, retatrutide should only be administered within the context of an approved clinical trial
Extending treatment to one year, the gap widens: about 4% greater weight loss in non-diabetics on semaglutide, and about 5.5% greater on tirzepatide. Some researchers suggest that behavioral differences such as motivation, adherence and engagement in lifestyle changes might help explain this gap
While this has not been conclusively proven in humans, the FDA has issued a warning for the potential risk